About Gennex Laboratories
Gennex Laboratories is a publicly listed company based in Hyderabad (India) founded in 1995. APIs are manufactured, marketed, and exported by Gennex Laboratories. The company has 115 employees. Its Indian entity Gennex Laboratories Limited reported revenue of ₹181 Cr. Gennex Laboratories offers products and services including Phenazopyridine Hcl, Methocarbamol, Mephenesin, Melitracen Hcl, and Guaifenesin. Its focus areas include Biopharma Outsourcing, CDMO and Small Molecules & Peptides. Similar companies include Indoco Remedies, Concord Biotech and BDR Pharmaceuticals Internationals; 1 of its 3 listed similar companies has raised funding.
Company details
Gennex Laboratories was established in 1995 in Hyderabad, India, within the pharmaceutical sector. APIs are produced, marketed, and exported to clients including major industry players in India and abroad. Operations focus on a product portfolio that includes expectorants, muscle relaxants, analgesics, and anti-fungals. Primary markets are served in Latin America, the Mid East, and Central Asia.
- Headquarters Hyderabad, India
- Employees 115
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website gennexlab.com
- Social LinkedIn
- Legal Name Gennex Laboratories Limited
- Market Cap₹213 Cr
GENNEX · BSE
- Share Price₹9.28
+6.06% today
- Revenue₹173 Cr
FY 2025-26 · +25.3% YoY
- EBITDA₹21.84 Cr
Margin 12.6%
- Net Profit₹19.00 Cr
FY 2025-26 · +4.1% YoY
- P/E (TTM)10.3x
P/B 0.9x
- Employee Count115
Associated legal entities of Gennex Laboratories
Gennex Laboratories operates through Gennex Laboratories Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Gennex Laboratories Limited Listed CIN L24230TG1990PLC011168 | Active | 29 Mar 1990 | Medak, Telangana | ₹181 Cr | 103 | 8 | View details |
Products & Services of Gennex Laboratories
Gennex Laboratories offers a comprehensive portfolio of products and services, including Phenazopyridine Hcl, Methocarbamol, Mephenesin, Melitracen Hcl, and Guaifenesin.
Active ingredient used for urinary tract pain relief.
Muscle relaxant for treating musculoskeletal conditions.
Skeletal muscle relaxant for medical applications.
Antidepressant and anxiolytic compound.
Expectorant to relieve cough and chest congestion.
Antipsychotic for mental health treatments.
Board of directors of Gennex Laboratories Limited (Gennex Laboratories)
Gennex Laboratories Limited is the primary company behind Gennex Laboratories. The board of Gennex Laboratories Limited currently have 6 directors; the longest-serving is Arihant Baid, appointed in 2012. 15 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Arihant Baid DIN 01171845 | Managing Director | 18 May 2012 | 14 yrs 5 mo | Gennex Laboratories Limited |
| Ranga Rao Pantulu Avasarala DIN 09003006 | Director | 21 Dec 2020 | 5 yrs 10 mo | Gennex Laboratories Limited |
| Amudala Sreeramulu Nageswar Rao DIN 07030259 | Director | 21 Dec 2020 | 5 yrs 10 mo | Gennex Laboratories Limited |
| Dilip Raj Singhvi DIN 00898902 | Director | 01 Oct 2024 | 2 yrs 1 mo | Gennex Laboratories Limited |
| Sandeep Kumar Daga DIN 00860908 | Director | 30 May 2025 | 1 yr 5 mo | Gennex Laboratories Limited |
| Khushbu Kachhawa DIN 10872432 | Director | 14 Feb 2026 | 8 mo | Gennex Laboratories Limited |
IPO & Listings of Gennex Laboratories
Gennex Laboratories is a publicly listed company on the BSE with ticker symbol GENNEX in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date23 May 1996
- Listed onBSE: 531739
- Listed entityGennex Laboratories Limited
- Exchange sectorHealth technology
- ISININE509C01026
- Share price₹9.43 (+2.39% on the day) · 2026-10-14
- Market capitalisation₹209 Cr
- Price to earnings11.8
- EPS (diluted, trailing year)₹0.80
- Volume (last session)250,105
Financials of Gennex Laboratories
Exchange-reported figures of Gennex Laboratories Limited, the listed company behind Gennex Laboratories (BSE: GENNEX).
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 173 | 138 | 86.71 | 65.61 | 61.21 | 59.65 | 55.62 |
| Revenue growth | +25.3% | +59.0% | +32.2% | +7.2% | +2.6% | +7.3% | - |
| EBITDA | 21.84 | 16.56 | 17.03 | 4.70 | 5.37 | 6.16 | 3.25 |
| EBITDA margin | +12.6% | +12.0% | +19.6% | +7.2% | +8.8% | +10.3% | +5.8% |
| Profit before tax | 23.24 | 21.39 | 16.49 | 6.38 | 5.08 | 5.06 | 2.56 |
| Net profit | 19.00 | 18.26 | 12.71 | 4.89 | 3.91 | 4.32 | 1.79 |
| Net profit margin | +11.0% | +13.2% | +14.7% | +7.5% | +6.4% | +7.2% | +3.2% |
| EPS (₹) | 0.76 | 0.80 | 0.58 | 0.27 | 0.31 | 0.32 | 0.15 |
| Balance sheet | |||||||
| Total assets | 312 | 222 | 195 | 104 | 53.94 | 47.09 | 40.67 |
| Net worth | 223 | 187 | 170 | 80.35 | 43.81 | 39.71 | 35.67 |
| Total debt | 35.95 | 10.22 | 5.72 | 1.05 | 10.12 | 7.36 | 4.98 |
| Cash & bank | 52.42 | 55.57 | 60.97 | 15.06 | 8.31 | 1.07 | 0.91 |
| Net working capital | 228 | 147 | 127 | 20.22 | 33.10 | 26.01 | 19.09 |
| Cash flow | |||||||
| Cash from operations | (63.65) | (9.56) | (46.69) | 23.68 | 11.91 | (1.44) | (1.67) |
| Cash from investing | (4.80) | 2.63 | 18.91 | (38.33) | (2.47) | (0.02) | (0.22) |
| Cash from financing | 65.30 | 1.53 | 73.68 | 21.03 | (1.83) | 1.62 | (0.35) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 39.84 | 60.96 | 42.96 | 39.30 | 34.18 | 40.33 | 40.01 | 33.38 |
| Revenue growth (YoY) | +16.6% | +51.2% | +7.4% | +17.7% | +20.7% | - | - | - |
| Other income | 2.01 | 1.32 | 0.00 | 0.00 | 2.28 | 3.83 | 0.00 | 0.00 |
| EBITDA | 4.38 | 5.59 | 8.28 | 7.55 | 5.07 | 1.87 | 7.16 | 7.45 |
| EBITDA margin | +11.0% | +9.2% | +20.5% | +20.3% | +14.8% | +4.6% | +19.0% | +23.6% |
| Depreciation | 0.90 | 1.16 | 0.52 | 0.47 | 0.50 | 0.54 | 0.50 | 1.11 |
| Interest | 0.57 | 1.08 | 1.11 | 1.03 | 0.98 | 1.20 | 0.84 | 0.22 |
| Profit before tax | 4.92 | 4.67 | 6.65 | 6.05 | 5.87 | 3.96 | 5.82 | 6.12 |
| Tax | 0.25 | 0.21 | 0.65 | 0.55 | 0.85 | 0.88 | 0.75 | 0.75 |
| Net profit | 4.67 | 4.46 | 6.00 | 5.50 | 5.02 | 3.08 | 5.07 | 5.37 |
| EPS (₹) | 0.19 | 0.16 | 0.22 | 0.21 | 0.21 | 0.14 | 0.22 | 0.21 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 120 | 94.58 | 66.80 | 65.10 | 61.21 | 59.65 | 55.62 |
| Revenue growth | +26.7% | +41.6% | +2.6% | +6.4% | +2.6% | +7.3% | - |
| EBITDA | 13.53 | 10.19 | 12.43 | 4.59 | 5.37 | 6.16 | 3.25 |
| EBITDA margin | +11.3% | +10.8% | +18.6% | +7.1% | +8.8% | +10.3% | +5.8% |
| Profit before tax | 18.23 | 17.06 | 14.76 | 6.02 | 5.08 | 5.06 | 2.56 |
| Net profit | 16.65 | 14.18 | 11.80 | 4.53 | 3.91 | 4.32 | 1.79 |
| Net profit margin | +13.9% | +15.0% | +17.7% | +7.0% | +6.4% | +7.2% | +3.2% |
| EPS (₹) | 0.67 | 0.62 | 0.52 | 0.25 | 0.31 | 0.32 | 0.15 |
| Balance sheet | |||||||
| Total assets | 245 | 191 | 173 | 81.29 | 54.12 | 47.25 | 40.85 |
| Net worth | 218 | 185 | 171 | 79.02 | 44.00 | 39.89 | 35.85 |
| Total debt | 22.82 | 1.24 | 0.85 | 0.98 | 10.12 | 7.36 | 4.98 |
| Cash & bank | 52.40 | 55.56 | 60.96 | 14.45 | 8.31 | 1.07 | 0.91 |
| Net working capital | 209 | 159 | 147 | 57.22 | 33.10 | 25.99 | 19.09 |
| Cash flow | |||||||
| Cash from operations | (40.18) | (9.52) | (33.43) | (14.45) | 6.64 | (1.44) | (1.67) |
| Cash from investing | 1.62 | 2.63 | 0.93 | (0.77) | (1.26) | (0.02) | (0.22) |
| Cash from financing | 35.40 | 1.53 | 79.01 | 21.35 | 1.87 | 1.62 | (0.35) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 34.68 | 36.71 | 30.72 | 31.37 | 25.64 | 23.28 | 27.35 | 26.51 |
| Revenue growth (YoY) | +35.3% | +57.7% | +12.3% | +18.3% | +20.2% | - | - | - |
| Other income | 2.00 | 1.30 | 0.00 | 0.00 | 2.26 | 2.87 | 0.00 | 0.00 |
| Total expenses | 31.72 | 33.83 | 24.86 | 25.37 | 22.26 | 23.21 | 21.78 | 20.98 |
| EBITDA | 2.96 | 2.88 | 5.86 | 6.00 | 3.38 | 0.07 | 5.57 | 5.53 |
| EBITDA margin | +8.5% | +7.8% | +20.8% | +20.5% | +13.2% | +0.3% | +22.0% | +22.4% |
| Depreciation | 0.24 | 0.35 | 0.21 | 0.21 | 0.20 | 0.53 | 0.20 | 0.05 |
| Interest | 0.51 | 0.63 | 0.69 | 0.55 | 0.59 | 0.23 | 0.41 | 0.47 |
| Profit before tax | 4.21 | 3.20 | 4.96 | 5.24 | 4.85 | 2.18 | 4.96 | 5.01 |
| Tax | 0.25 | 0.21 | 0.50 | 0.70 | 0.70 | 0.67 | 0.75 | 0.85 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 39.84 | 60.96 | 42.96 | 39.30 | 34.18 | 40.33 | 40.01 | 33.38 |
| Revenue growth (YoY) | +16.6% | +51.2% | +7.4% | +17.7% | +20.7% | - | - | - |
| Other income | 2.01 | 1.32 | 0.00 | 0.00 | 2.28 | 3.83 | 0.00 | 0.00 |
| EBITDA | 4.38 | 5.59 | 8.28 | 7.55 | 5.07 | 1.87 | 7.16 | 7.45 |
| EBITDA margin | +11.0% | +9.2% | +20.5% | +20.3% | +14.8% | +4.6% | +19.0% | +23.6% |
| Depreciation | 0.90 | 1.16 | 0.52 | 0.47 | 0.50 | 0.54 | 0.50 | 1.11 |
| Interest | 0.57 | 1.08 | 1.11 | 1.03 | 0.98 | 1.20 | 0.84 | 0.22 |
| Profit before tax | 4.92 | 4.67 | 6.65 | 6.05 | 5.87 | 3.96 | 5.82 | 6.12 |
| Tax | 0.25 | 0.21 | 0.65 | 0.55 | 0.85 | 0.88 | 0.75 | 0.75 |
| Net profit | 4.67 | 4.46 | 6.00 | 5.50 | 5.02 | 3.08 | 5.07 | 5.37 |
| EPS (₹) | 0.19 | 0.16 | 0.22 | 0.21 | 0.21 | 0.14 | 0.22 | 0.21 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 173 | 138 | 86.71 | 65.61 | 61.21 | 59.65 | 55.62 |
| Revenue growth | +25.3% | +59.0% | +32.2% | +7.2% | +2.6% | +7.3% | - |
| Other income | 8.25 | 10.43 | 4.91 | 3.95 | 1.38 | 0.52 | 1.06 |
| Total expenses | 151 | 121 | 69.68 | 60.91 | 55.84 | 53.49 | 52.37 |
| Employee cost | 0.00 | 8.35 | 7.79 | 7.87 | 6.97 | 7.21 | 6.81 |
| EBITDA | 21.84 | 16.56 | 17.03 | 4.70 | 5.37 | 6.16 | 3.25 |
| EBITDA margin | +12.6% | +12.0% | +19.6% | +7.2% | +8.8% | +10.3% | +5.8% |
| Depreciation | 2.65 | 1.99 | 2.37 | 0.92 | 0.79 | 0.88 | 1.00 |
| Interest | 4.20 | 3.61 | 3.08 | 1.35 | 0.88 | 0.74 | 0.75 |
| Profit before tax | 23.24 | 21.39 | 16.49 | 6.38 | 5.08 | 5.06 | 2.56 |
| Tax | 2.26 | 3.27 | 3.32 | 1.45 | 1.17 | 1.02 | 0.69 |
| Net profit | 19.00 | 18.26 | 12.71 | 4.89 | 3.91 | 4.32 | 1.79 |
| Net profit margin | +11.0% | +13.2% | +14.7% | +7.5% | +6.4% | +7.2% | +3.2% |
| EPS (₹) | 0.76 | 0.80 | 0.58 | 0.27 | 0.31 | 0.32 | 0.15 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 24.29 | 22.74 | 22.74 | 18.02 | 12.65 | 12.65 | 12.65 |
| Reserves & surplus | 198 | 158 | 142 | 62.33 | 31.16 | 27.06 | 23.02 |
| Shareholders' funds (net worth) | 223 | 187 | 170 | 80.35 | 43.81 | 39.71 | 35.67 |
| Minority interest | 10.32 | 7.90 | 6.08 | 6.17 | 0.00 | 0.00 | 0.00 |
| Secured loans | 35.95 | 10.22 | 5.72 | 1.05 | 10.12 | 7.36 | 4.98 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total debt | 35.95 | 10.22 | 5.72 | 1.05 | 10.12 | 7.36 | 4.98 |
| Total liabilities | 312 | 222 | 195 | 104 | 53.94 | 47.09 | 40.67 |
| Assets | |||||||
| Gross block | 84.64 | 81.37 | 75.51 | 91.51 | 30.61 | 30.34 | 30.26 |
| Net block | 60.73 | 59.55 | 55.64 | 73.73 | 13.69 | 14.12 | 14.93 |
| Capital work in progress | 13.32 | 5.22 | 2.32 | 0.02 | 0.00 | 0.00 | 0.00 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 6.83 | 6.83 | 6.83 |
| Inventories | 53.89 | 35.94 | 25.17 | 15.69 | 7.74 | 5.02 | 7.44 |
| Sundry debtors | 43.56 | 14.16 | 17.81 | 9.42 | 11.31 | 8.95 | 6.28 |
| Cash & bank balances | 52.42 | 55.57 | 60.97 | 15.06 | 8.31 | 1.07 | 0.91 |
| Loans & advances | 115 | 75.46 | 57.85 | 8.51 | 19.82 | 22.63 | 20.34 |
| Total current assets | 265 | 181 | 162 | 48.68 | 47.18 | 37.67 | 34.97 |
| Total current liabilities | 36.45 | 34.34 | 34.58 | 28.46 | 14.08 | 11.66 | 15.88 |
| Net working capital | 228 | 147 | 127 | 20.22 | 33.10 | 26.01 | 19.09 |
| Total assets | 312 | 222 | 195 | 104 | 53.94 | 47.09 | 40.67 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 55.57 | 60.96 | 15.06 | 8.68 | 1.07 | 0.91 | 3.15 |
| Net cash from operating activities | (63.65) | (9.56) | (46.69) | 23.68 | 11.91 | (1.44) | (1.67) |
| Net cash from investing activities | (4.80) | 2.63 | 18.91 | (38.33) | (2.47) | (0.02) | (0.22) |
| Net cash from financing activities | 65.30 | 1.53 | 73.68 | 21.03 | (1.83) | 1.62 | (0.35) |
| Net change in cash | (3.15) | (5.40) | 45.91 | 6.38 | 7.61 | 0.16 | (2.23) |
| Closing cash | 52.42 | 55.57 | 60.97 | 15.06 | 8.31 | 1.07 | 0.91 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +25.3% | +59.0% | +32.2% | +7.2% | +2.6% | +7.3% | - |
| EBITDA growth | +31.9% | -2.8% | +262.3% | -12.5% | -12.8% | +89.5% | - |
| PBT growth | +8.7% | +29.7% | +158.5% | +25.6% | +0.4% | +97.7% | -15.5% |
| Net income growth | +4.1% | +43.7% | +159.9% | +25.1% | -9.5% | +141.3% | - |
| Revenue CAGR (3Y) | +38.1% | +31.1% | +13.3% | +5.7% | +3.1% | +10.9% | +9.9% |
| EBITDA CAGR (3Y) | +66.9% | +45.6% | +40.4% | +13.1% | +10.1% | +41.2% | -10.4% |
| Profitability & leverage | |||||||
| Net income margin | +12.2% | +13.1% | +15.2% | +7.5% | +6.4% | +6.8% | +3.4% |
| Return on capital employed | - | +12.4% | +13.6% | +10.2% | +11.8% | +13.2% | +8.3% |
| Return on net worth | - | +10.2% | +10.5% | +7.9% | +9.4% | +10.7% | +5.3% |
| Debt / equity | - | 0.04 | 0.03 | 0.09 | 0.21 | 0.16 | 0.14 |
| Long-term debt / equity | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 21.89 | 24.78 | 21.01 | 35.71 | 19.21 | 14.02 | 33.33 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 1.98 | 1.18 | 1.18 | 2.14 | 2.10 | 1.99 |
| Inventory turnover | - | 5.11 | 4.81 | 6.13 | 10.23 | 10.22 | 9.39 |
| Debtors turnover | - | 9.77 | 7.22 | 6.93 | 6.44 | 8.36 | 7.19 |
| EPS (₹) | 0.76 | 0.80 | 0.58 | 0.27 | 0.31 | 0.32 | 0.15 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 7.96 | 7.24 | 4.46 | 3.46 | 3.14 | 2.82 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 34.68 | 36.71 | 30.72 | 31.37 | 25.64 | 23.28 | 27.35 | 26.51 |
| Revenue growth (YoY) | +35.3% | +57.7% | +12.3% | +18.3% | +20.2% | - | - | - |
| Other income | 2.00 | 1.30 | 0.00 | 0.00 | 2.26 | 2.87 | 0.00 | 0.00 |
| Total expenses | 31.72 | 33.83 | 24.86 | 25.37 | 22.26 | 23.21 | 21.78 | 20.98 |
| EBITDA | 2.96 | 2.88 | 5.86 | 6.00 | 3.38 | 0.07 | 5.57 | 5.53 |
| EBITDA margin | +8.5% | +7.8% | +20.8% | +20.5% | +13.2% | +0.3% | +22.0% | +22.4% |
| Depreciation | 0.24 | 0.35 | 0.21 | 0.21 | 0.20 | 0.53 | 0.20 | 0.05 |
| Interest | 0.51 | 0.63 | 0.69 | 0.55 | 0.59 | 0.23 | 0.41 | 0.47 |
| Profit before tax | 4.21 | 3.20 | 4.96 | 5.24 | 4.85 | 2.18 | 4.96 | 5.01 |
| Tax | 0.25 | 0.21 | 0.50 | 0.70 | 0.70 | 0.67 | 0.75 | 0.85 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 120 | 94.58 | 66.80 | 65.10 | 61.21 | 59.65 | 55.62 |
| Revenue growth | +26.7% | +41.6% | +2.6% | +6.4% | +2.6% | +7.3% | - |
| Other income | 8.14 | 9.22 | 4.30 | 3.40 | 1.38 | 0.52 | 1.06 |
| Total expenses | 106 | 84.39 | 54.37 | 60.51 | 55.84 | 53.49 | 52.37 |
| Employee cost | 0.00 | 6.42 | 6.05 | 7.71 | 6.97 | 7.21 | 6.81 |
| EBITDA | 13.53 | 10.19 | 12.43 | 4.59 | 5.37 | 6.16 | 3.25 |
| EBITDA margin | +11.3% | +10.8% | +18.6% | +7.1% | +8.8% | +10.3% | +5.8% |
| Depreciation | 0.97 | 0.77 | 0.81 | 0.74 | 0.79 | 0.88 | 1.00 |
| Interest | 2.47 | 1.58 | 1.16 | 1.23 | 0.88 | 0.74 | 0.75 |
| Profit before tax | 18.23 | 17.06 | 14.76 | 6.02 | 5.08 | 5.06 | 2.56 |
| Tax | 2.11 | 3.02 | 2.96 | 1.45 | 1.17 | 1.02 | 0.69 |
| Net profit | 16.65 | 14.18 | 11.80 | 4.53 | 3.91 | 4.32 | 1.79 |
| Net profit margin | +13.9% | +15.0% | +17.7% | +7.0% | +6.4% | +7.2% | +3.2% |
| EPS (₹) | 0.67 | 0.62 | 0.52 | 0.25 | 0.31 | 0.32 | 0.15 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 24.29 | 22.74 | 22.74 | 18.02 | 12.65 | 12.65 | 12.65 |
| Reserves & surplus | 194 | 156 | 142 | 61.00 | 31.35 | 27.24 | 23.20 |
| Shareholders' funds (net worth) | 218 | 185 | 171 | 79.02 | 44.00 | 39.89 | 35.85 |
| Secured loans | 22.82 | 1.24 | 0.85 | 0.98 | 10.12 | 7.36 | 4.98 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total debt | 22.82 | 1.24 | 0.85 | 0.98 | 10.12 | 7.36 | 4.98 |
| Total liabilities | 245 | 191 | 173 | 81.29 | 54.12 | 47.25 | 40.85 |
| Assets | |||||||
| Gross block | 41.42 | 38.60 | 34.08 | 32.62 | 30.61 | 30.34 | 30.26 |
| Net block | 21.64 | 19.66 | 15.83 | 15.18 | 13.69 | 14.12 | 14.93 |
| Capital work in progress | 5.18 | 2.62 | 1.38 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 8.26 | 8.26 | 8.26 | 8.26 | 7.01 | 7.01 | 7.01 |
| Inventories | 41.63 | 24.59 | 16.07 | 14.97 | 7.74 | 5.02 | 7.44 |
| Sundry debtors | 33.37 | 11.89 | 13.57 | 8.82 | 11.31 | 8.95 | 6.28 |
| Cash & bank balances | 52.40 | 55.56 | 60.96 | 14.45 | 8.31 | 1.07 | 0.91 |
| Loans & advances | 111 | 94.98 | 88.39 | 33.91 | 19.82 | 22.63 | 20.34 |
| Total current assets | 238 | 187 | 179 | 72.15 | 47.18 | 37.67 | 34.97 |
| Total current liabilities | 29.26 | 27.87 | 31.97 | 14.93 | 14.08 | 11.68 | 15.88 |
| Net working capital | 209 | 159 | 147 | 57.22 | 33.10 | 25.99 | 19.09 |
| Total assets | 245 | 191 | 173 | 81.29 | 54.12 | 47.25 | 40.85 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 55.60 | 60.96 | 14.45 | 8.31 | 1.07 | 0.91 | 3.15 |
| Net cash from operating activities | (40.18) | (9.52) | (33.43) | (14.45) | 6.64 | (1.44) | (1.67) |
| Net cash from investing activities | 1.62 | 2.63 | 0.93 | (0.77) | (1.26) | (0.02) | (0.22) |
| Net cash from financing activities | 35.40 | 1.53 | 79.01 | 21.35 | 1.87 | 1.62 | (0.35) |
| Net change in cash | (3.16) | (5.36) | 46.51 | 6.14 | 7.24 | 0.16 | (2.23) |
| Closing cash | 52.40 | 55.56 | 60.96 | 14.45 | 8.31 | 1.07 | 0.91 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +26.7% | +41.6% | +2.6% | +6.4% | +2.6% | +7.3% | - |
| EBITDA growth | +32.8% | -18.0% | +170.8% | -14.5% | -12.8% | +89.5% | - |
| PBT growth | +6.9% | +15.6% | +145.2% | +18.5% | +0.4% | +97.7% | -15.5% |
| Net income growth | +17.4% | +20.2% | +160.5% | +15.9% | -9.5% | +141.3% | - |
| Revenue CAGR (3Y) | +22.6% | +15.6% | +3.9% | +5.4% | +3.1% | +10.9% | +9.9% |
| EBITDA CAGR (3Y) | +43.4% | +23.8% | +26.4% | +12.2% | +10.1% | +41.2% | -10.4% |
| Profitability & leverage | |||||||
| Net income margin | +13.5% | +14.8% | +17.7% | +7.0% | +6.4% | +6.8% | +3.4% |
| Return on capital employed | - | +10.3% | +12.5% | +10.7% | +11.8% | +13.2% | +8.3% |
| Return on net worth | - | +7.9% | +9.5% | +7.4% | +9.4% | +10.7% | +5.3% |
| Debt / equity | - | 0.01 | 0.01 | 0.09 | 0.21 | 0.16 | 0.14 |
| Long-term debt / equity | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 19.67 | 16.77 | 9.98 | 31.95 | 19.21 | 14.02 | 33.33 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 2.89 | 2.22 | 2.26 | 2.14 | 2.10 | 1.99 |
| Inventory turnover | - | 5.17 | 4.77 | 6.28 | 10.23 | 10.22 | 9.39 |
| Debtors turnover | - | 8.26 | 6.61 | 7.09 | 6.44 | 8.36 | 7.19 |
| EPS (₹) | 0.67 | 0.62 | 0.52 | 0.25 | 0.31 | 0.32 | 0.15 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 7.87 | 7.26 | 4.39 | 3.48 | 3.15 | 2.83 |
Similar companies to Gennex Laboratories
Gennex Laboratories has 3 listed similar companies in our database, 1 of them funded. They include Indoco Remedies, Concord Biotech and BDR Pharmaceuticals Internationals.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| indoco.com | 1947 | Mumbai, India | 6,291 | APIs manufacturing and formulation services are provided in therapeutic segments. | ||
| concordbiotech.com | 2000 | Ahmedabad, India | 1,598 | APIs and enzymes are manufactured through fermentation by the CDMO. | ||
| bdrpharma.com | 2003 | Mumbai, India | $88.16M | 1,864 | APIs and finished products are developed and manufactured. |
Detailed similar companies of Gennex Laboratories
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Gennex Laboratories
The website of Gennex Laboratories (gennexlab.com) receives about 1.4K visits a month.
- Monthly visits1.4K
▲ 54.9% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Gennex Laboratories (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Gennex Laboratories
Complete news archive for Gennex Laboratories
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gennex Laboratories
Gennex Laboratories was founded in 1995.
Gennex Laboratories is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Gennex Laboratories has 115 employees.
The primary company behind Gennex Laboratories, Gennex Laboratories Limited, reported revenue of ₹181 Cr for FY 2026, up 25% year on year.
Gennex Laboratories was established in 1995 in Hyderabad, India, within the pharmaceutical sector. APIs are produced, marketed, and exported to clients including major industry players in India and abroad. Operations focus on a product portfolio that includes expectorants, muscle relaxants, analgesics, and anti-fungals. Primary markets are served in Latin America, the Mid East, and Central Asia.
Gennex Laboratories's top competitors include Concord Biotech, BDR Pharmaceuticals Internationals and Indoco Remedies.
Gennex Laboratories offers Phenazopyridine Hcl, Methocarbamol, Mephenesin, Melitracen Hcl, and 2 more products and services.
Yes, Gennex Laboratories is publicly traded on BSE under the ticker symbol GENNEX.
Gennex Laboratories operates through Gennex Laboratories Limited.
The legal entities of Gennex Laboratories currently have 8 directors, including Ranga Rao Pantulu Avasarala, Arihant Baid, Amudala Sreeramulu Nageswar Rao and others.